New combo therapy shows promise for tough lymphoma cases
NCT ID NCT04539444
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of two treatments—CD19/22 CAR-T cells (a type of immune cell therapy) and tislelizumab (a PD-1 inhibitor that helps immune cells attack cancer)—in 18 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal was to see if the combo could shrink tumors or slow disease progression. Results are not yet widely available, but the study aims to offer a new option for patients who have run out of standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19/22 CAR-T cells and tislelizumab (PD-1 inhibitor)
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat B-cell lymphoma that has not responded to standard therapies.
What could go wrong
This is a small, early-phase trial with only 18 participants, so results may not apply broadly. CAR-T therapy carries risks like severe immune reactions and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China